Erenumab for Preventive Treatment of Migraine: A Systematic Review and Meta-Analysis of Efficacy and Safety-Reference-Cited by-同舟云学术

Erenumab for Preventive Treatment of Migraine: A Systematic Review and Meta-Analysis of Efficacy and Safety

Published:2019-02-22 Issue:4 Volume:79 Page:417-431
ISSN:0012-6667
Container-title:Drugs
language:en
Short-container-title:Drugs

Author:

Lattanzi Simona^ORCID,Brigo Francesco,Trinka Eugen,Vernieri Fabrizio,Corradetti Tommaso,Dobran Mauro,Silvestrini Mauro

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical)

Link

http://link.springer.com/article/10.1007/s40265-019-01069-1/fulltext.html

Reference48 articles.

1. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2163–96.

2. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia. 2004;24 (Suppl. 1):9–160.

3. Headache Classification Committee of the International Headache Society. The international classification of headache disorders, 3rd edition (beta version). Cephalalgia. 2013;33:629–808.

4. Buse DC, Rupnow MF, Lipton RB. Assessing and managing all aspects of migraine: migraine attacks, migraine-related functional impairment, common comorbidities, and quality of life. Mayo Clin Proc. 2009;84:422–35.

5. Serrano D, Manack AN, Reed ML, Buse DC, Varon SF, Lipton RB. Cost and predictors of lost productive time in chronic migraine and episodic migraine: results from the American Migraine Prevalence and Prevention (AMPP) Study. Value Health. 2013;16:31–8.

Cited by 81 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Changes in use of acute and preventive medications for migraine after erenumab initiation over 12 months: A United States retrospective cohort study;Headache: The Journal of Head and Face Pain;2024-09-09

2. Impact of Erenumab on Migraine Disability: A Three-Month MIDAS (Migraine Disability Assessment Scale) Score Analysis at Dubai Health Facilities;Cureus;2024-08-18

3. Real-world effectiveness and safety of erenumab for the treatment of migraine: A systematic review and meta-analysis;European Journal of Pharmacology;2024-08

4. A 12-week randomized double-blind clinical trial of eicosapentaenoic acid intervention in episodic migraine;Brain, Behavior, and Immunity;2024-05

5. An update on migraine;JAAPA;2024-04-25